Targeting Bacteroides in stool microbiome and response to treatment with first-line VEGF tyrosine kinase inhibitors in metastatic renal-cell carcinoma
AW Hahn, C Froerer, S VanAlstine, N Rathi…�- Clinical genitourinary�…, 2018 - Elsevier
Background Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are
a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome composition is
predictive of response to immunotherapy and cytotoxic chemotherapy. We sought to
investigate whether antibiotics targeting Bacteroides species affect progression-free survival
(PFS) while receiving first-line VEGF-TKI therapy. Patients and Methods Using a
retrospective cohort of intermediate-and poor-risk metastatic renal-cell carcinoma patients�…
a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome composition is
predictive of response to immunotherapy and cytotoxic chemotherapy. We sought to
investigate whether antibiotics targeting Bacteroides species affect progression-free survival
(PFS) while receiving first-line VEGF-TKI therapy. Patients and Methods Using a
retrospective cohort of intermediate-and poor-risk metastatic renal-cell carcinoma patients�…